Clinical Trials Logo

Filter by:
NCT ID: NCT04143997 Withdrawn - Clinical trials for Diastolic Dysfunction

Diastolic Dysfunction PPCM in Patients With Documented Left Ventricular Systolic Function Recovery

Start date: November 1, 2019
Phase:
Study type: Observational

The purpose of this project is to evaluate parameters of diastolic dysfunction assessed by clinical echocardiogram in patients who have had recovery of systolic function.

NCT ID: NCT04143529 Withdrawn - Clinical trials for Musculoskeletal Malignancy

Preoperative Mindfulness In Musculoskeletal Tumor

Start date: November 2019
Phase: N/A
Study type: Interventional

Psychosocial distress is common in patients with an oncologic diagnosis, with anxiety being present in almost 20-30% of the patients.[1, 2, 10] Mindfulness exercises have shown to reduce this distress.[4, 5] Recently, the implementation of a 60-second mindfulness-based intervention has shown to have momentary effects on pain, anxiety, depression and anger in orthopaedic upper extremity patients.[9] However, its lasting effect after the single intervention was not evaluated. Nonetheless, because the intervention is not time consuming and is easy to implement it may benefit orthopaedic oncology patients in their pre-operative coping. The implementation of a 60-second mindfulness-based intervention has shown to have momentary effects on pain, anxiety, depression and anger in orthopaedic upper extremity participants. In this research study, the investigators are studying a 60-second interactive personalized acceptance-based mindfulness exercise

NCT ID: NCT04143113 Withdrawn - Ischemic Stroke Clinical Trials

Decision Aid Feasibility Trial for Families of Critically Ill Stroke Patients

Start date: July 1, 2020
Phase: N/A
Study type: Interventional

Severe strokes, including large artery acute ischemic stroke and intracerebral hemorrhage, continue to be the leading cause of death and disability in adults in the U.S. Due to concerns for a poor long-term quality of life, withdrawal of mechanical ventilation and supportive medical care with transition to comfort care is the most common cause of death in severe strokes, but occurs at a highly variable rate. Decision aids (DAs) are shared decision-making tools which have been successfully implemented and validated for many other diseases to assist difficult decision making. The investigators have developed a pilot DA for goals-of-care decisions for surrogates of severe, critically ill stroke patients. This was developed through qualitative research using semi-structured interviews in surrogate decision makers of traumatic brain injury patients and physicians, and adapted to severe strokes. The investigators now propose to pilot-test a DA for surrogates of critically ill severe stroke patients in a feasibility trial.

NCT ID: NCT04140539 Withdrawn - Clinical trials for Severe Combined Immunodeficiency Due to ADA Deficiency

A Clinical Study to Enable Process Validation of Commercial Grade OTL-101

Start date: October 15, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of the current study is to treat at least 3 ADA-SCID patients with OTL-101 prepared by the commercial manufacturing process.

NCT ID: NCT04140513 Withdrawn - Clinical trials for Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer

Start date: October 9, 2020
Phase: N/A
Study type: Interventional

This trial studies how well digital PET scan works in predicting outcomes in patients with oropharyngeal cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced). The development of digital detectors for PET is a technological improvement in medical imaging that could potentially impact many areas of clinical oncology, including staging, radiation planning accuracy, and the assessment of treatment response. Digital technology may improve PET imaging performance by providing better timing, energy and spatial resolution, higher count rate capabilities and linearity, increased contrast, and reduced noise. Utilizing digital PET scan, may work better in predicting outcomes and treatment response in patients with oropharyngeal cancer compared to conventional PET.

NCT ID: NCT04140279 Withdrawn - Ocular Hypertension Clinical Trials

A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension

Start date: May 13, 2022
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to determine the effect of latanoprostene bunod (LBN) ophthalmic solution 0.024% (a single dose and 7 days of once daily [QD] dosing) on 2 aspects of aqueous humor (AqH) dynamics (episcleral venous pressure [EVP] and outflow facility) in participants with ocular hypertension (OHT).

NCT ID: NCT04139694 Withdrawn - Insulin Resistance Clinical Trials

Improving Insulin Resistance in Gynecological Cancer Patients

Start date: March 16, 2020
Phase: N/A
Study type: Interventional

This is a research study to see if the addition of cinnamon to a provided food plan would improve insulin resistance in gynecological cancer patients. One study suggests that patients with gynecological cancers are more likely to be insulin resistant and/or have higher levels of fasting insulin. The study will be 24 weeks in length.

NCT ID: NCT04139395 Withdrawn - Clinical trials for Fever of Unknown Origin

68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO)

Start date: January 15, 2019
Phase: Phase 3
Study type: Interventional

This is a Phase III study to evaluate 68Ga Citrate PET/MRI for detection of origin of fever of unknown origin.

NCT ID: NCT04138875 Withdrawn - Clinical trials for Hematopoietic/Lymphoid Cancer

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Start date: January 2022
Phase: Phase 2
Study type: Interventional

This is an open label, risk-stratified, sequential treatment, phase 2 study of newly diagnosed post-transplant lymphoproliferative disorders with positive CD20 and CD30 expression. It includes an induction phase with rituximab and brentuximab vedotin (RBv), followed by a treatment phase with RBv or RBv in combination with bendamustine (RBvB) based on response to induction. The primary end point is treatment efficacy measured as the overall response rate (ORR) and progression free survival (PFS).

NCT ID: NCT04138602 Withdrawn - Fecal Incontinence Clinical Trials

BTL Emsella Chair Versus Sham for the Treatment of Fecal Incontinence

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to compare the Emsella Chair to sham and to determine whether electromagnetic technology is effective in the treatment of fecal incontinence. Currently there are no other studies utilizing the Emsella Chair for the treatment of fecal incontinence. Eligible subjects will receive 2 treatments per week for a total of 4 weeks.